Table 3

Outcome of patients undergoing active surveillance61

Percent of patients (95% CI)
5 years10 years
Disease specific survival
Grade 198 (96 to 99)87 (81 to 91)
Grade 297 (93 to 98)87 (80 to 92)
Grade 367 (51 to 79)34 (19 to 50)
Metastasis-free survival
Grade 193 (90 to 95)81 (75 to 86)
Grade 284 (79 to 89)58 (49 to 66)
Grade 351 (36 to 64)26 (13 to 41)